The IDH1 case highlights important insights to identify cancer-derived COMF mutations, including: (i) focusing on mutations that are recurrent, (ii) concentrating on mutations in functional enzyme structures such as the active site (iii) using unbiased metabolite profiling to reveal unexpected gained functions. Here, IDH1 is linked to cancer.